Pacific Biosciences Of California (PACB) Enterprise Value (2010 - 2026)

Pacific Biosciences Of California's Enterprise Value history runs 17 years deep, the most recent figure standing at -$276.0 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 19.57% year-over-year to -$276.0 million in Q1 2026; TTM through Mar 2026 was -$276.0 million, a 19.57% increase from a year earlier, with the FY2025 full-year figure at -$63.7 million, down 2088.43% from the prior year.
• Enterprise Value eased to -$276.0 million in Q1 2026 per PACB's latest filing, from -$63.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$2.9 million in Q4 2024 and bottomed at -$874.9 million in Q1 2023.
• The 5-year median for Enterprise Value is -$343.1 million (2025), against an average of -$353.8 million.
• Across the five-year window, Enterprise Value soared 99.33% in 2023 and sank 13551.22% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$450.5 million in 2022, then surged by 99.33% to -$3.0 million in 2023, then rose by 3.64% to -$2.9 million in 2024, then sank by 2088.43% to -$63.7 million in 2025, then slumped by 333.04% to -$276.0 million in 2026.
• Per Business Quant, the three latest PACB Enterprise Value figures stand at -$276.0 million (Q1 2026), -$63.7 million (Q4 2025), and -$244.0 million (Q3 2025).